Berberine Effects in Pre-Fibrotic Stages of Non-Alcoholic Fatty Liver Disease—Clinical and Pre-Clinical Overview and Systematic Review of the Literature
Authors:
- Florentina Ionita-RaduFIFlorentina Ionita-Radu
- Cristina PatoniCPCristina Patoni
- Andreea Simona NancoffANAndreea Simona Nancoff
- Flavius-Stefan MarinFMFlavius-Stefan Marin
- Laura GamanLaura Gaman
- Ana BucuricaABAna Bucurica
- Calin SocolCSCalin Socol
- Mariana JingaMJMariana Jinga
- Madalina DutuMadalina Dutu
- Sandica BucuricaSBSandica Bucurica
Open Access
- 10 April 2024
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (8) , 4201
Abstract
Non-alcoholic fatty liver disease (NAFLD) is the predominant cause of chronic liver conditions, and its progression is marked by evolution to non-alcoholic steatosis, steatohepatitis, cirrhosis related to non-alcoholic steatohepatitis, and the potential occurrence of hepatocellular carcinoma. In our systematic review, we searched two databases, Medline (via Pubmed Central) and Scopus, from inception to 5 February 2024, and included 73 types of research (nine clinical studies and 64 pre-clinical studies) from 2854 published papers. Our extensive research highlights the impact of Berberine on NAFLD pathophysiology mechanisms, such as Adenosine Monophosphate-Activated Protein Kinase (AMPK), gut dysbiosis, peroxisome proliferator-activated receptor (PPAR), Sirtuins, and inflammasome. Studies involving human subjects showed a measurable reduction of liver fat in addition to improved profiles of serum lipids and hepatic enzymes. While current drugs for NAFLD treatment are either scarce or still in development or launch phases, Berberine presents a promising profile. However, improvements in its formulation are necessary to enhance the bioavailability of this natural substance.Keywords
Funding Information
- Carol Davila University of Medicine and Pharmacy through the institutional program Publish
This publication has 161 references indexed in Scilit:
- Compromised hepatic mitochondrial fatty acid oxidation and reduced markers of mitochondrial turnover in human NAFLDHepatology, 2022
- Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double‐Blind Phase 2 TrialHepatology, 2021
- Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR StudyHepatology, 2020
- Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver diseaseCellular and Molecular Life Sciences, 2018
- Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory scienceHepatology, 2018
- Noninvasive, Quantitative Assessment of Liver Fat by MRI‐PDFF as an Endpoint in NASH TrialsHepatology, 2018
- Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitisHepatology, 2017
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver DiseasesHepatology, 2017
- The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trialHepatology, 2017
- Comparison of dietary polyphenols for protection against molecular mechanisms underlying nonalcoholic fatty liver disease in a cell model of steatosisMolecular Nutrition & Food Research, 2017